Bristol-Myers slumps as EU and USA delay lung cancer filings

Click here to view original web page at

Shares in Bristol-Myers Squibb fell 6% on Monday, after the firm made public regulatory setbacks in the…

To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.

Related posts

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.